Replies to post #440856 on Amarin Corp Plc (AMRN)

[Whalatane]

Hi Lem. , My wife is a Nephrology PA and rounds several dialysis clinics .
They haven't prescribed Vascepa or any " fish oil " because of lack of data specific for dialysis patients .
So this study is creating a lot of buzz at Kidney wk and elsewhere
Another take

American Society of Nephrology Annual Meeting
nephrology news and issues logo
ByLucas Laboy
Fish oil supplementation may reduce CVD risks for people on dialysis

November 08, 2025
2 min read
Add topic to email alerts

Save

Share
Key takeaways:
The fish oil group reported a significantly lower rate of CV events vs. placebo.
Future research should explore mechanisms behind omega-3 supplements for kidney disease, according to researchers.
HOUSTON — Fish oil supplementation showed efficacy in reducing risks for cardiovascular events for patients on dialysis, according to data from the PISCES trial presented at ASN Kidney Week.

Use of omega-3 supplements, a type of polyunsaturated fatty acids that includes eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been explored for potential CV health benefits, according to Charmaine E. Lok, MD, MSc, FRCPC, professor of medicine at the University of Toronto and senior scientist at the Toronto General Hospital Research Institute. However, supplementation in a patient population on hemodialysis has not been established, despite patients on dialysis having a 20 times greater risk for CV death, according to Lok.

Graphic distinguishing meeting news
“There really is no recommendation in terms of should you take fish oil supplementation or not, particularly in capsule form,” Lok said during a press briefing at ASN Kidney Week.

To test the efficacy of fish oil supplements for the dialysis population, Lok and colleagues conducted a double-blind, randomized, placebo-controlled trial at 26 sites across Canada and Australia from 2013 to 2019.

Results were simultaneously published in The New England Journal of Medicine.


Patients on hemodialysis were randomly assigned into two groups: 610 patients (mean age, 64.1 years; 62.2% men; 40% white) received 4 g steam-deodorized, citrus-flavored omega-3 fatty acids, and 618 patients (n = 618; mean age, 64.5 years; 63.1% men; 39.5% white) received citrus-flavored corn oil placebo. The fish oil group received four 1 g capsules containing 1.6 g EPA and 0.8 g DHA.

The primary outcome focused on a composite of severe CV events — myocardial infarction resulting in amputation, stroke, peripheral vascular disease and CVD death. The secondary endpoints were noncardiac cause death, individual CV event rates and all-cause mortality.

After a follow-up period of 3.5 years, the fish oil group had a significantly lower rate of CV events compared with the placebo group (0.31 per 1,000 patient-days vs. 0.61; HR = 0.57; 95% CI, 0.47-0.7).

Including noncardiac causes of death, the fish oil group had a lower mortality rate compared with placebo (HR = 0.77; 95% CI, 0.65-0.9).

For individual risk factors, the fish oil group had reduced risks for CV death (HR = 0.55; 95% CI, 0.4-0.75), myocardial infarction (HR = 0.56; 95% CI, 0.4-0.8), peripheral vascular disease (HR = 0.57; 95% CI, 0.38-0.86), stroke (HR = 0.37; 95% CI, 0.18-0.76) and all-cause mortality (HR = 0.73; 95% CI, 0.61-0.87).

The data show daily fish oil supplementation reduced the risk for CVD for patients on hemodialysis. According to Lok, understanding the mechanisms behind supplementation can help to explore its benefits for patients with kidney disease.

Lok_Charmaine_2025_80x106
Charmaine E. Lok
“What we really need to do is try to look into the mechanisms of action,” Lok told Healio. “We have a lot of data, and I think there’s a lot of work for us to unravel the effects and why they occurred.”

For more information:
Charmaine E. Lok, MD, MSc, FRCPC, can be reached at [e-mail].

Published by:
nephrology news and issues logo
--------------------------------------
Event lines separated at about 6 mths ...trial was for only 3.5 yrs
Anyone have access to the NEJM article and comments

Kiwi

[TastyTheElf]

The potential impact of any management team, including this one, has now been minimized.  The US is a tight ship, and someone else is handling Europe and then just paying us.  The company now can focus on the only thing it's ever been good at -- writing papers and going to conferences. The drug is starting to sell itself.
Denner and his board have turned this thing into a patent holding company that just prints cash.  The idiotic market will not be able to ignore this for much longer.  If it tries to, they'll just buy back all the stock.